RideNow Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that RideNow Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $1.79B | Mar 16, 2023 |
| FY2022 | Dec 31, 2021 | $924.17M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $416.43M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $840.63M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $156.40M | May 29, 2020 |
| FY2018 | Dec 31, 2017 | $7.31M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Feb 14, 2017 |
| FY2016 | Nov 30, 2015 | $0 | Feb 14, 2017 |
| FY2014 | Nov 30, 2014 | $0 | Mar 17, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.08B | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.21B | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.37B | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.46B | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $924.17M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $416.43M | Apr 8, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $298.00M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $314.30M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $359.90M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $441.70M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $158.18M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $31.63M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $50.62M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $13.55M | May 29, 2020 |
| FY2018 | Dec 31, 2017 | $278.1K | Apr 1, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($52.40M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($78.60M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($215.50M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($261.50M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($9.73M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($25.00M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($45.18M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($25.18M) | May 29, 2020 |
| FY2018 | Dec 31, 2017 | ($8.57M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($224.6K) | Feb 27, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($200.0K) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($15.20M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($69.50M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($260.10M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($8.87M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($18.56M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($37.79M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($23.40M) | May 29, 2020 |
| FY2018 | Dec 31, 2017 | ($7.98M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($213.4K) | Feb 27, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $1.42M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $2.41M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.15M | May 29, 2020 |
| FY2014 | Nov 30, 2014 | $0 | Mar 17, 2015 |
| FY2014 | Nov 30, 2013 | $1.6K | Mar 17, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $256.30M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $275.40M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $347.30M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $354.50M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $164.08M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $53.66M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $86.62M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $35.96M | May 29, 2020 |
| FY2018 | Dec 31, 2017 | $7.59M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $211.5K | Feb 27, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.90M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $99.40M | Mar 13, 2026 |
| FY2022 | Dec 31, 2022 | ($18.89M) | Mar 16, 2023 |
| FY2022 | Dec 31, 2021 | ($32.18M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $17.14M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($39.75M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($23.45M) | May 29, 2020 |
| FY2018 | Dec 31, 2017 | ($9.62M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($20.0K) | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | ($5.9K) | Feb 14, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.60M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.00M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $13.70M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $5.60M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $5.65M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $175.0K | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $119.7K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.4K | May 29, 2020 |
| FY2018 | Dec 31, 2017 | $622.5K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Feb 27, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $673.60M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $755.20M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $926.30M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.03B | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.03B | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $76.98M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $113.39M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $108.93M | May 29, 2020 |
| FY2018 | Dec 31, 2017 | $18.15M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.40M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $686.10M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $718.50M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $820.70M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $821.20M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $596.10M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $72.41M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $100.51M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $78.11M | May 29, 2020 |
| FY2018 | Dec 31, 2017 | $3.79M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $304.3K | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.50M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $36.70M | Mar 13, 2026 |
| FY2025 | Dec 31, 2023 | $105.60M | Mar 13, 2026 |
| FY2024 | Dec 31, 2022 | $206.00M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $431.60M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $4.57M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $12.89M | Apr 8, 2022 |
| FY2020 | Dec 31, 2018 | $30.82M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $14.37M | May 29, 2020 |
| FY2018 | Dec 31, 2016 | $1.09M | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $800.0K | Mar 13, 2026 |
| FY2025 | Dec 31, 2023 | $800.0K | Mar 13, 2026 |
| FY2024 | Dec 31, 2022 | $21.10M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $234.80M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $26.89M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $26.89M | Apr 8, 2022 |
| FY2020 | Dec 31, 2018 | $26.11M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $1.85M | May 29, 2020 |
| FY2017 | Dec 31, 2016 | $0 | Feb 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($712.30M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($659.90M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($591.10M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($375.60M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($114.11M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($104.38M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($79.38M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($34.20M) | May 29, 2020 |
| FY2018 | Dec 31, 2017 | ($9.02M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($446.0K) | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.50M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $85.30M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $58.90M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $46.80M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $48.97M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.47M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $49.7K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $9.13M | May 29, 2020 |
| FY2018 | Dec 31, 2017 | $9.17M | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $1.35M | Apr 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $207.60M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $251.10M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $274.30M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $598.20M | Mar 28, 2024 |
| FY2021 | Dec 31, 2021 | $257.91M | Apr 8, 2022 |
| FY2020 | Dec 31, 2020 | $5.18M | Mar 31, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (12) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | (16) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | (11) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | (40) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | (33) | May 29, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Feb 27, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (12) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | (16) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | (11) | Apr 8, 2022 |
| FY2016 | Dec 31, 2016 | 0 | Feb 14, 2017 |
| FY2016 | Dec 31, 2015 | 0 | Feb 14, 2017 |
| FY2016 | Nov 30, 2015 | 0 | Feb 14, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | 6.40M | Feb 14, 2017 |
| FY2016 | Dec 31, 2015 | 5.50M | Feb 14, 2017 |
| FY2016 | Nov 30, 2015 | 5.50M | Feb 14, 2017 |
| FY2015 | Nov 30, 2014 | 5.00M | Mar 14, 2016 |
| FY2014 | Nov 30, 2013 | 5.00M | Mar 17, 2015 |